These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24512488)

  • 21. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.
    Russo D; Ottaggio L; Penna I; Foggetti G; Fronza G; Inga A; Menichini P
    Biochem Biophys Res Commun; 2010 Nov; 402(2):345-50. PubMed ID: 20946886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
    Lee JK; Kim KC
    Biochem Biophys Res Commun; 2013 Sep; 438(4):647-52. PubMed ID: 23933322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
    Wang T; Lee K; Rehman A; Daoud SS
    Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
    Cai L; Wang Z; Liu D
    Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53.
    Zache N; Lambert JM; Wiman KG; Bykov VJ
    Cell Oncol; 2008; 30(5):411-8. PubMed ID: 18791272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins.
    Rökaeus N; Klein G; Wiman KG; Szekely L; Mattsson K
    Oncogene; 2007 Feb; 26(7):982-92. PubMed ID: 16909106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
    Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
    Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway.
    Zhang P; Yang X; Ma X; Ingram DR; Lazar AJ; Torres KE; Pollock RE
    Mol Cancer; 2015 Mar; 14():55. PubMed ID: 25890085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.
    Saha MN; Jiang H; Yang Y; Reece D; Chang H
    Mol Cancer Ther; 2013 Nov; 12(11):2331-41. PubMed ID: 24030633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep.
    Li Y; Ren Y; Wang Y; Tan Y; Wang Q; Cai J; Zhou J; Yang C; Zhao K; Yi K; Jin W; Wang L; Liu M; Yang J; Li M; Kang C
    Theranostics; 2019; 9(16):4608-4623. PubMed ID: 31367244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deazaneplanocin a is a promising drug to kill multiple myeloma cells in their niche.
    Gaudichon J; Milano F; Cahu J; DaCosta L; Martens AC; Renoir JM; Sola B
    PLoS One; 2014; 9(9):e107009. PubMed ID: 25255316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3-BrPA eliminates human bladder cancer cells with highly oncogenic signatures via engagement of specific death programs and perturbation of multiple signaling and metabolic determinants.
    Konstantakou EG; Voutsinas GE; Velentzas AD; Basogianni AS; Paronis E; Balafas E; Kostomitsopoulos N; Syrigos KN; Anastasiadou E; Stravopodis DJ
    Mol Cancer; 2015 Jul; 14():135. PubMed ID: 26198749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
    Hayden A; Johnson PW; Packham G; Crabb SJ
    Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.
    Wiman KG
    Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells.
    Lee K; Wang T; Paszczynski AJ; Daoud SS
    Biochem Biophys Res Commun; 2006 Oct; 349(3):1117-24. PubMed ID: 16970918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells.
    Girard N; Bazille C; Lhuissier E; Benateau H; Llombart-Bosch A; Boumediene K; Bauge C
    PLoS One; 2014; 9(5):e98176. PubMed ID: 24852755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.
    Rehman A; Chahal MS; Tang X; Bruce JE; Pommier Y; Daoud SS
    Breast Cancer Res; 2005; 7(5):R765-74. PubMed ID: 16168122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3-deazaneplanocin A protects against cisplatin-induced renal tubular cell apoptosis and acute kidney injury by restoration of E-cadherin expression.
    Ni J; Hou X; Wang X; Shi Y; Xu L; Zheng X; Liu N; Qiu A; Zhuang S
    Cell Death Dis; 2019 May; 10(5):355. PubMed ID: 31043583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model.
    Akpa CA; Kleo K; Oker E; Tomaszewski N; Messerschmidt C; López C; Wagener R; Oehl-Huber K; Dettmer K; Schoeler A; Lenze D; Oefner PJ; Beule D; Siebert R; Capper D; Dimitrova L; Hummel M
    BMC Cancer; 2020 May; 20(1):427. PubMed ID: 32408898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.